Systemic lupus erythematous (SLE) is a chronic inflammatory disease that predominantly affects women and can involve virtually any organ. The authors of this study analyzed secular trends and population characteristics associated with SLE mortality. Objective: Mortality statistics from the Centers for Disease Control and Prevention (CDC) are used for planning healthcare policy and allocating resources….
Results from Belimumab Safety Study
In a long-term extension study, belimumab proved safe, demonstrating low organ damage accrual in SLE patients treated for up to nine years…
Neutrophils & B Cells Create Unique Antibodies in Lupus Patients
NETs or LL37-DNA complexes may serve as future targets for SLE therapy. In a recent study, researchers identified a link between neutrophils and NETs, and the activation of self-reactive B cells. Their study describes a neutrophil-B cell interaction unique to lupus…
Lupus & Cognitive Dysfunction: No Apparent Link to Inflammation
Does cognitive dysfunction in SLE patients result from persistent inflammation characterized by ongoing disease activity? Recent research examining this question found no inflammatory mechanism associated with cognitive dysfunction in this patient population, underscoring previous research findings…
Is Chemical Exposure Linked to DNA Methylation Dysregulation in SLE Patients?
Could your lupus patients benefit from limiting exposure to chemicals at home and in the medical environment? It’s a strong possibility, according to the preliminary findings of a research team investigating DNA methylation disruption in patients with SLE…
Insight into the Downregulation of NK Cells in SLE Patients
New research suggests the downregulation of CD3ζ contributes to the altered function of NK cells in SLE patients, which may contribute to the increased risk of viral infections in these patients…
Subcutaneous Belimumab Improves Systemic Lupus Srythematosus Outcomes
NEW YORK (Reuters Health)—Subcutaneous belimumab improves outcomes in anti-dsDNA-positive hypocomplementemic patients with systemic lupus erythematosus (SLE), according to results from a Phase 3 randomized, controlled trial. Intravenous belimumab is approved by the U.S. Food and Drug Administration and the European Medicines Agency for the treatment of patients with active, autoantibody-positive SLE who are receiving standard…
New Classification Criteria for SLE: Proposed ACR/EULAR Criteria aim for high sensitivity & specificity
SAN DIEGO—The proposed classification criteria for systemic lupus erythematosus (SLE), supported but not yet approved by the ACR and EULAR, were debuted on Nov. 7 at the 2017 ACR/ARHP Annual Meeting. An international steering committee developed and validated the criteria, with patient input and the consensus of more than 150 global SLE experts. Rheumatology researchers…
The Pop Star Effect & Lupus: Celebrity Cred May Help Raise Awareness of Rheumatic Disease
This year, Selena Gomez underwent a kidney transplant as a result of damage from living with lupus. But how can this celebrity story aid rheumatologists? Many see it as an opportunity to raise awareness or create a dialogue with primary care physicians. But for lupus patients, it can be a reminder for them to take control of their own wellbeing, according to rheumatologist Susan Manzi, MD, MPH…
European Commission Approves Subcutaneous Belimumab for SLE; FDA Safety Alert for Febuxostat
Subcutaneous belimumab has been approved in the EU to help treat patients with active autoantibody-positive SLE…
- « Previous Page
- 1
- …
- 5
- 6
- 7
- 8
- 9
- …
- 12
- Next Page »